Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis

What Was Tested

The paper reports a study of Glatiramer Acetate in the context of multiple sclerosis, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Fifty-five participants were randomly assigned (1:1 ratio) to either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy initiated in all participants.

Participants were followed up to 3 years.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Glatiramer Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Glatiramer Acetate.

A placebo (an inactive look-alike) gave the Glatiramer Acetate group a baseline to be compared against.

The methods mention a period of 3 years.

This was a single-center, double-blind, placebo-controlled study.

The primary endpoint was the number of participants with no evidence of disease activity (NEDA): those without relapse, new MRI lesions, and sustained change in disability.

What Was Measured

Topics PubMed links to this paper include Brain, Demyelinating Diseases, Glatiramer Acetate, Immunologic Factors, Immunosuppressive Agents, Induction Chemotherapy and Magnetic Resonance Imaging.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glatiramer Acetate in people with multiple sclerosis over 3 years.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Neurology), a journal based in United States.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.